| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Conrad Falkson | Q57617264 |
| P2093 | author name string | J Maroun | |
| J Siddiqui | |||
| S Gill | |||
| S Singh | |||
| D Grant | |||
| S Welch | |||
| J Biagi | |||
| S Edwards | |||
| L Williams | |||
| C Cripps | |||
| N Hammad | |||
| R Goel | |||
| C Quinton | |||
| M Tehfe | |||
| N Perrin | |||
| S Snow | |||
| C Marginean | |||
| R Goodwin | |||
| B Colwell | |||
| M Rother | |||
| B Samson | |||
| A Jeyakumar | |||
| F Wright | |||
| S Bourque | |||
| M Dorreen | |||
| E St-Hilaire | |||
| D Frechette | |||
| M Thirlwell | |||
| T Di Valentin | |||
| M L'espérance | |||
| M Nantais | |||
| P Champion | |||
| R Butt | |||
| V Chaput | |||
| P2860 | cites work | KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours | Q27824868 |
| KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 | Q27851532 | ||
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | Q28268831 | ||
| High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? | Q47406642 | ||
| Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. | Q51597657 | ||
| Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. | Q51597972 | ||
| Palliative management of malignant rectosigmoidal obstruction. Colostomy vs. endoscopic stenting. A randomized prospective trial. | Q51702640 | ||
| Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. | Q52846071 | ||
| Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer | Q56601042 | ||
| Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma | Q72866285 | ||
| Rectal tumour staging: MR imaging using pelvic phased-array and endorectal coils vs endoscopic ultrasonography | Q73744656 | ||
| Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer | Q80938561 | ||
| Systematic review of microsatellite instability and colorectal cancer prognosis | Q28303189 | ||
| Molecular predictors of survival after adjuvant chemotherapy for colon cancer | Q28363159 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 | ||
| Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer | Q29620038 | ||
| Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial | Q33415864 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients | Q33710999 | ||
| Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial | Q34041573 | ||
| Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin | Q34131764 | ||
| Incurable stenosing colorectal carcinoma: endoscopic stent implantation or palliative surgery? | Q34569231 | ||
| Local staging of rectal cancer: the current role of MRI. | Q34571377 | ||
| Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. | Q34587751 | ||
| One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. | Q34636998 | ||
| Diagnosis of gastrointestinal stromal tumors: a consensus approach | Q34697685 | ||
| Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. | Q34725978 | ||
| Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. | Q34743609 | ||
| The role of methadone in cancer pain treatment--a review | Q34990113 | ||
| Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. | Q35170271 | ||
| Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach. | Q35537640 | ||
| Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical evidence? A systematic review | Q35754341 | ||
| Rectal cancer: review with emphasis on MR imaging | Q35852152 | ||
| First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas | Q36335402 | ||
| Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin | Q36620016 | ||
| Reporting colorectal cancer. | Q36699554 | ||
| What is the role for the circumferential margin in the modern treatment of rectal cancer? | Q37053363 | ||
| Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials | Q37072114 | ||
| Neoadjuvant chemoradiation for rectal cancer: is more better? | Q37213166 | ||
| Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. | Q37475406 | ||
| Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: an updated practice guideline | Q37852375 | ||
| The role of collegial interaction in continuing professional development | Q38444765 | ||
| Treatment of malignant intestinal obstruction. A prospective study over 80 cases | Q39363603 | ||
| New grades for recommendations from the Canadian Task Force on Preventive Health Care | Q39796234 | ||
| Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease | Q40888760 | ||
| Comparison of outcome of open and laparoscopic resection for stage II and stage III rectal cancer | Q42615126 | ||
| Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids | Q43408021 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | e455-64 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | Current Oncology | Q3498968 |
| P1476 | title | Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stromal tumours and pancreatic neuroendocrine tumours | |
| P478 | volume | 20 |
| Q34362184 | Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. |
| Q90231424 | Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care |
| Q38637958 | Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions |
| Q64097859 | Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience |
Search more.